Resmed presents a once-in-10-year opportunity!
Marc Kennis, October 6, 2023
Don’t be daft…buy ResMed
Stuart Roberts shares his views on ResMed (ASX:RMD) shares, which have seen a 30% decrease in value since the beginning of August. Stuart considers this sell-off to be an overreaction. He stresses the impact of weight loss drugs, such as Ozempic, doesn’t mean RMD’s business would start dwindling.
Don’t miss out on important news about ASX-listed stocks!
SIGN UP FOR THE STOCKS DOWN UNDER NEWSLETTER!
Stuart highlights that ResMed has consistently maintained a high growth rate, even going back to before the global financial crisis. He anticipates that there will be a realisation that the underlying market for the company is substantially larger than the existing patient base. He rejects the interpretation that there is anything fundamentally wrong with the stock. Instead, he claims the company is in a stronger position now than ever before.
Stuart expects future growth will be driven by increased awareness of sleep apnea, investments in the company’s digital services and the existence of only three main competitors in the market.
Stuart commends ResMed’s successful investment of 7% of its revenue into R&D, yielding an array of impressive tools, setting the stage for sustained growth for the enterprise. Check out our recent article on Resmed!
Watch the interview below!
Blog Categories
Recent Posts
Bapcor (ASX:BAP): Its been a horror week with a 3rd profit downgrade in less than a year
This week investors in Bapcor (ASX:BAP) saw a 3rd profit downgrade in less than a year and its CEO-elect walk…
Is there another Asian financial crisis brewing? How would stocks be impacted?
Is there another Asian financial crisis brewing? There is increasing concern there might be as many Asian countries’ currencies struggle…
Why can’t ASX small bank stocks beat the Big 4?
Be disappointed all you like at the performance of some of the Big 4, but ASX small bank stocks have…